公开(公告)号：US20200299411A9

公开(公告)日：2020-09-24

申请号：US16345012

申请日：2017-10-26

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Andrew SATLIN ,  Tatsuto FUKUSHIMA

IPC: C07K16/44 ,  A61K31/542 ,  A61P25/28

Abstract: Methods and combination therapies for treating, preventing, and/or delaying the onset and/or development of Alzheimer's disease using an anti-Aβ protofibril antibody (such as, for example, BAN2401) and N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide and/or a pharmaceutically acceptable salt thereof (Compound X) are provided.

公开(公告)号：US20230146896A1

公开(公告)日：2023-05-11

申请号：US17857931

申请日：2022-07-05

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Andrew Satlin ,  Tatsuto FUKUSHIMA

IPC: C07K16/44 ,  A61P25/28 ,  A61K31/542 ,  C07K14/47 ,  C07K16/18 ,  A61K39/395

CPC classification number: C07K16/44 ,  A61P25/28 ,  A61K31/542 ,  C07K14/4711 ,  C07K16/18 ,  A61K39/3955 ,  C07K2317/24 ,  A61K2039/505

Abstract: Methods and combination therapties for treating, preventing, and/or delaying the onset and/or development of Alzheimer's disease using an anti Aβ protofibril (such as, for example, BAN2401) and N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1-,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide and/or a pharmaceutically acceptable salt thereof (Compound X) are provided.

公开(公告)号：US20190276560A1

公开(公告)日：2019-09-12

申请号：US16345012

申请日：2017-10-26

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Andrew SATLIN ,  Tatsuto FUKUSHIMA

IPC: C07K16/44 ,  A61K31/542 ,  A61P25/28

Abstract: Methods and combination therapies for treating, preventing, and/or delaying the onset and/or development of Alzheimer's disease using an anti-Aβ protofibril antibody (such as, for example, BAN2401) and N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide and/or a pharmaceutically acceptable salt thereof (Compound X) are provided.